Effect of famotidine on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor.

Disclosure VVU, YS, JW, JMP, FL, and CEF are employees of Bristol-Myers Squibb and received salaries and benefits commensurate with employment at the time of the study. WB and RAB are employees of Pfizer and received salaries and benefits commensurate with employment at the time of the study. This study was funded by Bristol-Myers Squibb and Pfizer. Professional medical writing and editorial assistance was provided by Andy Shepherd and Dana Fox at Caudex Medical, and was funded by Bristol-Myers Squibb and Pfizer.